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Abstract
Background—Owing to increasing sulfadoxine-pyrimethamine (SP) resistance in sub-Saharan 
Africa, monitoring the effectiveness of intermittent preventive therapy in pregnancy (IPTp) with 
SP is crucial.
Methods—Between 2009 and 2013, both the efficacy of IPTp-SP at clearing existing peripheral 
malaria infections and the effectiveness of IPTp-SP at reducing low birth weight (LBW) were 
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assessed among human immunodeficiency virus–uninfected participants in 8 sites in 6 countries. 
Sites were classified as high, medium, or low resistance after measuring parasite mutations 
conferring SP resistance. An individual-level prospective pooled analysis was conducted.
Results—Among 1222 parasitemic pregnant women, overall polymerase chain reaction–
uncorrected and –corrected failure rates by day 42 were 21.3% and 10.0%, respectively (39.7% 
and 21.1% in high-resistance areas; 4.9% and 1.1% in low-resistance areas). Median time to 
recurrence decreased with increasing prevalence of Pfdhps-K540E. Among 6099 women at 
delivery, IPTp-SP was associated with a 22% reduction in the risk of LBW (prevalence ratio [PR], 
0.78; 95% confidence interval [CI], .69–.88; P < .001). This association was not modified by 
insecticide-treated net use or gravidity, and remained significant in areas with high SP resistance 
(PR, 0.81; 95% CI, .67–.97; P = .02).
Conclusions—The efficacy of SP to clear peripheral parasites and prevent new infections 
during pregnancy is compromised in areas with >90% prevalence of Pfdhps-K540E. Nevertheless, 
in these high-resistance areas, IPTp-SP use remains associated with increases in birth weight and 
maternal hemoglobin. The effectiveness of IPTp in eastern and southern Africa is threatened by 
further increases in SP resistance and reinforces the need to evaluate alternative drugs and 
strategies for the control of malaria in pregnancy.
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Each year, approximately 32 million pregnancies in Africa are at risk of Plasmodium 
falciparum (Pf) infection [1]. Malaria in pregnancy (MiP) is associated with severe anemia, 
low birth weight (LBW), and perinatal mortality, primarily during the first and second 
pregnancies [2].
A cornerstone of MiP prevention is intermittent preventive therapy in pregnancy (IPTp) with 
sulfadoxine-pyrimethamine (SP) [3]. Administered as IPTp, SP both clears existing 
infections that consist of drug-sensitive parasites (treatment effect) and prevents incident 
infections (prophylactic effect) [4]. IPTp-SP reduces the risk of maternal anemia, LBW, and 
neonatal mortality [4,5], and the World Health Organization now recommends a dose of SP 
at each scheduled antenatal care (ANC) visit starting as early as possible in the second 
trimester [6, 7]. Currently, 33 malaria-endemic countries in Africa employ IPTp for MiP 
control [8,9], and SP remains the only antimalarial recommended for IPTp [6].
The effectiveness of IPTp in eastern and southern Africa is threatened by parasite resistance 
to SP, conferred by the successive acquisition of polymorphisms in the parasite genes 
encoding the targets of sulphadoxine and pyrimethamine: dihydropteroate synthase (Pfdhps) 
and dihydrofolate reductase (Pfdhfr), respectively. To varying degrees, these mutations are 
prevalent throughout Africa, and their association with the failure of SP treatment in 
children has rendered SP unsuitable for therapy. Nevertheless, even in areas where parasites 
routinely harbor up to 5 Pfdhfr and Pfdhps resistance-conferring mutations (the Pfdhfr–
Pfdhps “quintuple mutant” haplotype), SP has remained effective as IPTp, presumably 
owing to pregnant women's acquired, partial immunity [4, 7]. However, the recent 
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emergence of a more highly resistant “sextuple mutant” parasite in Tanzania was associated 
with a loss of IPTp-SP efficacy [10, 11]. Because prior parasite mutations have disseminated 
widely in Africa and undermined antimalarial policies [12, 13], further studies are needed to 
quantify the impact of molecular markers of SP resistance on the efficacy of IPTp-SP across 
Africa.
We conducted multicountry studies [14–19] in sub-Saharan Africa to investigate 2 effects of 
IPTp-SP: (1) its efficacy at clearing existing peripheral infections in asymptomatic pregnant 
women receiving their first dose of IPTp-SP; and (2) the effectiveness of IPTp-SP at 
increasing mean birth weight, reducing LBW, or improving other birth outcomes. Here we 
present individual-level pooled analyses of peripheral parasite clearance and birth outcomes 
to better quantify the impact of SP resistance on IPTp-SP effectiveness.
Methods
Study Sites and Study Period
The studies were conducted between 2009 and 2013 at 8 sites in 6 countries: 2 countries in 
West Africa (Mali [2 sites] and Burkina Faso [16]) and 4 in eastern and southern Africa 
(Zambia [19, 20], Malawi [2 sites] [15, 17, 21], Uganda [14], and Kenya [18]).
Study Design
In Vivo Module: 42-Day In Vivo Follow-up—To determine the efficacy of IPTp-SP in 
clearing existing peripheral Pf malaria infections or preventing new infections, prospective 
single-arm 42-day in vivo treatment efficacy studies of single-dose SP were conducted in all 
sites except Uganda. Eligible women were human immunodeficiency virus (HIV)–
uninfected, asymptomatic women of any gravidity who were due to receive their first dose 
of IPTp-SP according to national guidelines, with parasitemia confirmed by microscopy. 
The study design was identical, except in Zambia where the study duration was limited to 35 
days because national treatment guidelines recommend monthly IPTp-SP. The study was 
designed to detect a parasitological failure risk of 10% in primigravidae and secundigravidae 
(G1-G2 [paucigravidae]) and 5% in multigravidae (G3+) with 10% and 5% precision, 
respectively, allowing for 15% loss to follow-up. This required 162 paucigravidae and 86 
multigravidae per site; however, not all sites met these requirements. Following informed 
consent, a brief clinical examination; axillary temperature measurement; and collection of 
blood by fingerprick for malaria smears, rapid diagnostic tests, and filter-paper dried blood 
spots (DBSs) for polymerase chain reaction (PCR) were performed at enrollment and then 
weekly at the antenatal clinic. IPTp-SP was administered at enrollment and at the end of 
follow-up. Women who were smear positive on or after day 4 were classified as failing 
treatment, and received rescue treatment according to national guidelines. A sample of SP 
from each batch in each site was assessed and met the criteria for quality assurance (content 
analysis and dissolution) according to the United States Pharmacopeia monograph for SP 
tablets [22].
Molecular Module—In the in vivo study, microscopically detected peripheral parasite 
recurrence within 42 days was classified as recrudescence or reinfection by comparing 
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alleles of parasite genes encoding merozoite surface proteins 1 and 2 and glutamate-rich 
protein, using standard PCR methods and genomic DNA extracted from DBSs [23].The 
frequency of polymorphisms conferring parasite SP resistance at each study site was 
estimated using a pooled second-generation sequencing approach on parasites collected 
prior to SP receipt [24]. For each site, genomic DNA was pooled from women at enrollment 
in the in vivo studies (except Uganda, for which samples from children aged 6–59 months 
with acute uncomplicated malaria were used), amplified across Pfdhfr and Pfdhps loci 
conferring SP resistance (Pfdhfr codons 51, 59, 108, and 164, and Pfdhps codons 436, 437, 
540, 581, and 613), and sequenced on a Roche GS Junior instrument (454 Life Sciences, 
Branford, Connecticut). The returned reads were quality-filtered, aligned to reference 
sequences, and manually scored for polymorphisms in Pfdhfr and Pfdhps that confer SP 
resistance [24].
Delivery Module—To determine the impact of IPTp-SP on the prevalence of adverse 
maternal and newborn outcomes, facility-based crosssectional studies were conducted at the 
time of delivery among HIV-uninfected women of any gravidity at all sites. Following 
informed consent obtained at delivery, participant ANC cards and clinic records were 
examined for information on doses of IPTp-SP, and peripheral and placental samples 
(DBSs, impression smear, and/or histology) collected. Maternal hemoglobin (Hb) was 
measured with HemoCue (HemoCue Inc, Cypress, California); anemia was defined as Hb < 
11 g/dL and moderate-to-severe anemia as Hb < 9 g/dL. Newborns were weighed using 
digital scales (±10 g) and gestational age was assessed by Ballard score within 12 hours of 
birth, except in Uganda where only the date of the last menstrual period was available. LBW 
was defined as birth weight <2500 g and preterm delivery as gestational age <37 weeks. 
Small for gestational age (SGA) was defined as birth weight for gestational age <10th 
percentile using an ultrasound-derived fetal size nomogram [25]. Women enrolled in the in 
vivo studies were excluded from the delivery surveys. Individual studies were designed to 
detect a 2-fold difference in the prevalence of LBW or placental malaria in women who had 
received ≥2 doses of IPTp-SP vs none; sample sizes varied between 507 and 1103 
depending on the prevailing prevalence of the endpoint and SP use.
Ethics Statement
The protocols were approved locally in each country and by the Liverpool School of 
Tropical Medicine (Liverpool, United Kingdom) and the Centers for Disease Control and 
Prevention (Atlanta, Georgia). Written informed consent was obtained from each woman.
Data Analyses
For the in vivo module, modified intention-to-treat analysis was used. We assessed 
therapeutic response to treatment by the Kaplan–Meier product limit formula to calculate the 
cumulative risks of recurrence of asexual parasites (unadjusted and PCR adjusted for 
reinfections) [26] and compared failure risk across sites by gravidity group using 
proportional hazards regression [16].
In the delivery module, we investigated the relationship between the number of SP doses 
and delivery outcomes and employed propensity scores to minimize the potential for 
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confounding of these relationships (see Supplementary Data for further details) [27, 28]. For 
binary outcomes, a Poisson distribution was assumed, allowing the results to be reported as 
prevalence ratios (PRs) and corresponding 95% confidence intervals (CIs) for each 
incremental dose of IPTp-SP. For continuous variables, results were expressed as the mean 
difference (MD) and 95% CI for each incremental dose of IPTp-SP. Forest plots report the 
sample sizes, summary statistics, and PRs or MDs and 95% CIs for the raw and weighted 
analyses. The primary outcomes were LBW, mean birth weight, and placental parasitemia.
Finally, we used meta-regression to determine the potential for SP resistance to modify the 
effectiveness of IPTp, where SP resistance was expressed either as the in vivo failure rate or 
as the frequency of the A437G, K540E, or A581G mutations in the parasite Pfdhps gene, 
which predict the frequency of quadruple, quintuple, and sextuple Pfdhfr–Pfdhps mutant 
haplotypes, respectively.
Results
In Vivo Module
Between July 2009 and May 2012, a total of 1222 asymptomatic parasitemic pregnant 
women were enrolled in 6 in vivo studies (7 sites) in 5 countries (Supplementary Figure 1); 
1064 (87.1% [range, 66.3%–95.1%]) were followed successfully until the day of recurrence 
or completion of follow-up. The majority of women were paucigravidae (66.8%), with a 
mean gestational age of 23.5 weeks (Table 1). Use of insecticide-treated nets (ITNs) the 
night prior to enrollment varied from 21.7% (Zambia) to 77.1% (Mali).
Parasites from all sites except Mali and Burkina Faso harbored high frequencies (>90%) of 
mutations in Pfdhfr, except at locus 164, at which mutations were absent; in contrast, 
mutations in Pfdhps were more variable across sites, ranging from 27.5% to 100%, 0% to 
100%, and 0% to 5.7% at codons 437, 540, and 581, respectively (Table 1; Supplementary 
Table 2). For further analyses of resistance, we classified sites based on the frequencies of 
Pfdhps-K540E mutation: high resistance (Kenya, Uganda, and both sites in Malawi) (>90% 
Pfdhps-K540E); moderate resistance (Zambia) (50%–90% Pfdhps-K540E); or low 
resistance (<50% Pfdhps-K540E) (Mali and Burkina Faso). By days 28 and 42, the pooled 
PCR-uncorrected risks of recurrence were 15.2% (95% CI, 13.3%–17.4%) and 21.3% (95% 
CI, 19.0%–23.8%), respectively; corresponding PCR-corrected failure risks (recrudescence) 
were 7.6% (95% CI, 6.2%–9.3%) and 10.0% (95% CI, 8.3%–11.9%). Recrudescence was 
more common among paucigravidae than multigravidae (adjusted hazard ratio, 2.7 [95% CI, 
1.7–4.5]).
There was a trend toward increasing risk of treatment failure by the degree of SP resistance 
(Figure 1): the PCR-uncorrected risk of recurrence by day 42 was 4.9% in low-resistance 
sites, 21.0% in the single moderate-resistance site, and 39.7% in the high-resistance sites. 
PCR-corrected 42-day recrudescence rates were 1.1%, 10.7%, and 21.1% for the 3 
categories, respectively (Supplementary Table 3). Therefore, relative to low resistance sites, 
the risks of treatment failure were 9.6- and 23.0-fold higher in moderate- and high-resistance 
sites, respectively (Supplementary Table 3). The median time to recurrence decreased with 
increasing prevalence of Pfdhps-K540E and ranged from 42 days in Mali to 18 days in 
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Machinga, Malawi, reflecting differences in reinfection rather than time to recrudescence 
(Figure 2).
Delivery Module
Between July 2009 and April 2013, 6099 delivering women were enrolled between 7 studies 
at 8 sites in 6 countries; 45.1% of them were paucigravidae (Table 1). Approximately half 
(49.4%) had received exactly 2 doses of antenatal SP; 9.4%, 23.8%, and 17.4% had received 
zero, 1, or ≥3 doses, respectively. Most women who received zero doses were from Mali 
(46.3%) or Burkina Faso (31.1%); most women who received ≥3 doses were from Kenya 
(47.3%) or Blantyre, Malawi (35.5%). ITN use the night prior to enrollment varied from 
35.6% (Machinga, Malawi) to 95.6% (Kenya).
Overall, 9.6% of infants were LBW (Table 2). Overall, each dose of antenatal SP was 
associated with a 22% reduction in the risk of LBW (PR, 0.78 [95% CI, .69–.88]; P < .001; 
Figure 3). After stratification into 3 resistance strata, the effect of each dose of SP was 
similar in low-resistance (PR, 0.75 [95% CI, .64–.88]; P = .001), moderate-resistance (PR, 
0.73 [95% CI, .51–1.03]; P = .07), and high-resistance areas (PR, 0.81 [95% CI, .67–.97]; P 
= .02) (Figure 3). Furthermore, meta-regression indicated that the effect of SP on the risk of 
LBW was not modified by resistance (Figure 4; Supplementary Figure 2). The effect of 
IPTp-SP did not differ significantly by ITN use (P value interaction term = .93) or gravidity 
(P value interaction term = .38) (Figure 3; Supplementary Table 4).
Overall, each incremental dose of IPTp-SP was associated with a mean increase of 49 g 
(95% CI, 22–76 g; P < .001) in birth weight (Table 2; Figure 3). This association varied 
between SP resistance strata: Each dose of SP was associated with 111-g (95% CI, 71–151 
g; P < .001) and 56-g (95% CI, 18–94 g; P = .004) increases in the moderate- and high-
resistance strata, respectively (Figure 3), but not in the low-resistance strata (mean increase, 
20 g [95% CI, −20 to 59 g]; P = .33). Overall, there was no evidence for a linear relationship 
between the effect on mean birth weight and resistance (Figure 3; Supplementary Table 5). 
Additionally, there was no evidence of effect modification by ITN use (P = .38) or gravidity 
(P = .22) (Supplementary Table 4).
Each dose of IPTp-SP was associated with an increase in maternal Hb (MD, 0.26 g/dL [95% 
CI, .16–.36 g/dL]; P < .001) and less moderate-to-severe anemia (Hb < 9 g/dL; PR, 0.85 
[95% CI, .79–.92]; P = .001); these associations were similar across the gravidity groups, 
among ITN users and nonusers (Supplementary Table 4), and across resistance strata 
(Supplementary Figures 9, 11, 21, and 23). IPTp-SP was also associated with a 23% lower 
risk of placental infection detected by impression smear (PR, 0.77 [95% CI, .63–.94]; P = .
01), and a nonsignificant reduction in peripheral malaria (PR, 0.84 [95% CI, .69–1.02]; P = .
07; Figure 5), and this was not modified by resistance levels (Table 2; Supplementary Table 
5).
Discussion
Our analyses show that SP resistance mutations compromise the clearance of parasites in 
pregnant women. Compared with the Malian sites with the lowest prevalence of resistance 
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markers, the risk of SP failure was 23- to 40-fold higher in high-resistance sites in eastern 
Africa. In addition, high-resistance sites had a greater number of reinfections and a shorter 
time to reinfection during the 42-day follow-up, suggesting that SP resistance attenuates the 
effectiveness of SP to prevent new infections. Despite this, our findings indicate that, even 
in areas with high SP resistance, IPTp-SP is associated with beneficial impacts on birth 
weight and maternal Hb.
In areas with high SP resistance, which include much of eastern and southern Africa, SP was 
associated with a 19% reduction in LBW and a 15% reduction in maternal anemia at 
delivery. The association with reduced LBW was present in multigravidae as well as 
paucigravidae, consistent with a previous meta-analysis of clinical trials that compared 2-
dose IPTp-SP with more frequent doses [7]. It is surprising that parasite SP resistance, as 
expressed both by parasite molecular markers and by in vivo efficacy of parasite clearance, 
did not affect the associations between IPTp-SP and birth outcomes: Irrespective of 
resistance, IPTp-SP is associated with a similar reduction in LBW and increase in maternal 
Hb. This finding may be explained by several factors. There may be a difference in the 
degree to which resistance affects the ability of IPTp-SP to treat or prevent infections vs the 
ability to prevent malaria-associated morbidity if partial suppression of parasitemia may be 
sufficient to reduce some of the adverse effect on fetal growth and maternal anemia. SP may 
also have secondary, off-target effects on bacterial or fungal infections that promote fetal 
growth and maternal health [31]. The impact of SP may also be affected by attributable 
fraction of malaria to LBW and thus malaria transmission intensity and the degree of 
protective immunity among pregnant women. Last, malaria is only one of many causes of 
LBW, and the relationship between population levels of parasite resistance and effectiveness 
of SP on LBW is likely to be affected by the prevalence of other risk factors, thus requiring 
larger sample sizes to show a trend.
It has been suggested that further increases in the level of resistance may result in a more 
definitive loss of the effectiveness of IPTp-SP. Two recent studies from northeastern 
Tanzania suggested that SP failed to inhibit growth of parasites with the sextuple haplotype 
[10, 11]; that is, parasites that harbor the quintuple mutant Pfdhfr–Pfdhps haplotype along 
with the additional Pfdhps-A581G mutation. These parasites are known to be associated 
with increased treatment failure in patients with acute malaria [32]. Women harboring these 
highly resistant parasites had higher parasite densities [33], more placental inflammation 
[10], and newborns with lower birth weights than women infected with parasites with the 
quintuple mutation who received IPTp-SP [11]. Taken together, these data suggest that the 
additional Pfdhps-A581G mutation, which confers a greater level of resistance than the 
quintuple mutant, should be included in the molecular surveillance of SP resistance to guide 
IPTp-SP implementation.
Several limitations must be noted. Among women enrolled at delivery, those who received 
fewer doses of IPTp-SP may have also received less antenatal care in general, and frequency 
of ANC visits is associated with birth weight [34]. However, the number of ANC visits was 
not collected as part of our surveys, precluding adjustment. Also, although all sites used the 
documented number of SP courses as the primary source of exposure data, not all sites 
verified with the participant whether she had actually taken these courses. In Zambia and 
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Uganda, the policy to use high-dose folic acid (5 mg) during ANC may have resulted in an 
overestimation of the SP treatment failure rates [35]. Furthermore, loss to follow-up in the 
Zambia and Machinga, Malawi sites was 33.7% and 38.8%, respectively, but baseline 
characteristics were similar among completers and noncompleters. The prevalence of LBW 
and preterm birth was lower and the mean gestational age at delivery higher (41.6 weeks) at 
the Machinga, Malawi site compared with the other sites. Sensitivity analysis to assess the 
effect of removing the Machinga study showed no change in overall conclusion (data not 
shown). The bimodal distribution of SP resistance in our studies limited our ability for trend 
analysis: 7 of the 8 sites clustered at the 2 extremes of the resistance spectrum, with only a 
single study representative of moderate resistance, consistent with known partitioning of 
mutant Pfdhps haplotypes across sub-Saharan Africa. Furthermore, none of the studies were 
conducted in areas such as northern Tanzania, which has a much higher prevalence (>50%) 
of parasites harboring the sextuple mutant haplotype. Finally, we were unable to assess the 
correlation between malaria transmission intensity and IPTp-SP effectiveness in this limited 
sample of studies.
This is the first prospective multicountry effort to link population-level parasite SP 
resistance to the efficacy and effectiveness of IPTp-SP. Our pooled analysis suggests that, 
with increasing resistance, there is a progressively diminished efficacy of IPTp-SP in 
clearing existing infections and a shortening of the posttreatment prophylaxis period. 
Although concerning, our analysis also suggests that IPTp-SP remains associated with 
improvements in birth weight and maternal hemoglobin level in areas where the prevalence 
of the Pfdhps-K540E mutation was >90%, but where the additional Pfdhps-A581G mutation 
was still rare. Although parasites harboring the Pfdhfr–Pfdhps quintuple mutant are now 
highly prevalent in areas across eastern and southern Africa, the sextuple mutant parasites 
are still uncommon, but are spreading [36–38]. Our data underline the need for studying 
alternative drugs for IPTp and alternative strategies to IPTp, such as intermittent screening 
and treatment during pregnancy. Our data also suggest that molecular surveillance of SP 
resistance could be a useful tool to guide IPTp-SP implementation.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Parasitological failure rates among asymptomatic, parasitemic pregnant women receiving 
their first dose of intermittent preventive therapy in pregnancy with sulfadoxine-
pyrimethamine (SP). The protocol in Zambia administered SP at 1 month and thus only 
contributes data through day 35 inclusive in this analysis. The therapeutic response was 
estimated using the Kaplan–Meier product limit formula [26]. In the polymerase chain 
reaction (PCR)–uncorrected analysis, recurrences were treated as treatment failures, and all 
other events (eg, withdrawal or protocol deviations) resulted in censoring at the time of that 
event, or at the time of their last follow-up visit in case of loss to follow-up. A similar 
strategy was used for the PCR-corrected analysis, except that patients with new Plasmodium 
falciparum infections (reinfections) were censored at the time of parasite reappearance [26]. 
To compare the failure risk across sites, hazard ratios (HRs) were estimated using Cox 
regression adjusting for gravidity and net use with a shared frailty component to account for 
the individual heterogeneity of the sites. Abbreviations: CI, confidence interval; ref, 
reference.
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Figure 2. 
Median time to recurrence, recrudescence or reinfection of Plasmodium falciparum among 
women participating in the intermittent preventive therapy in pregnancy in vivo module. A, 
Median time to recurrence by frequency of pyrimethamine: dihydropteroate synthase 
(Pfdhps)-K540E. The circles represent the estimated median time to recurrence of P. 
falciparum infection at each site, sized according to the precision of each estimate (the 
inverse of its within-study variance, σ2). The line represents the linear prediction of the 
relationship between median time to recurrence and prevalence of Pfdhps-K540E. B, 
Median time in days by study site, ranked by resistance level. Abbreviations: CI, confidence 
interval; IPTp, intermittent preventive therapy in pregnancy.
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Figure 3. 
Associations between each incremental dose of intermittent preventive therapy in pregnancy 
with sulfadoxine-pyrimethamine (SP) and mean birth weight and the prevalence of low birth 
weight, stratified by SP resistance, gravidity, and insecticide-treated net use. Abbreviations: 
CI, confidence interval; SD, standard deviation.
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Figure 4. 
Meta-regression bubble plot of the prevalence of low birth weight (LBW) by the frequency 
of the pyrimethamine: dihydropteroate synthase (Pfdhps)-K540E mutation (8 sites, top 
panel) and in vivo failure rates in asymptomatic pregnant women (7 sites, bottom panel). 
The Tororo site in Uganda did not conduct an in vivo study and is missing from the bottom 
panel. The circles represent the estimated prevalence ratio of LBW, sized according to the 
sample size from each site. The gray area represents the 95% confidence interval, and the 
dotted line is the linear prediction. In the bottom panel, the prevalence ratio of LBW was 
regressed against the polymerase chain reaction (PCR)–corrected failure rate by day 35, as 
this was the latest standardized day available from all countries (in Zambia, the study was 
ended on day 35 rather than on day 42). The numbers under each site represent the 
prevalence ratio and its confidence limit.
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Figure 5. 
Associations between each incremental dose of intermittent preventive therapy in pregnancy 
with sulfadoxine-pyrimethamine and all secondary outcomes. aGestational age, determined 
by Ballard score or where unavailable by last menstrual period, was missing from a variable 
number of individuals at each site; data completeness varied from 76% to 
100%. bHemoglobin level (g/dL), assessed by HemoCue at delivery. cSmall for gestational 
age defined as birth weight for gestational age <10th percentile using an ultrasound-derived 
fetal size nomogram for a sub-Saharan African population [25]. dMalaria infection defined 
as either a positive peripheral smear (maternal malaria) or a positive placental impression 
smear (composite endpoint). eActive placental infection (acute or chronic) by placental 
histology, classified on a 5-point scale as described by Rogerson et al [30]. Placental 
histology was not done in the 3 sites in West Africa (low resistance strata). Abbreviations: 
CI, confidence interval; SD, standard deviation.
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